Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease

Neurological Sciences

Volumn 27, Issue 6, 2006, Pages 397-401

  Ottaviani, Sarah ^a   Tinazzi, M ^a,b   Pasquin, I ^c   Nothdurfter, W ^b   Tomelleri, G ^a   Fincati, E ^b   Nordera, G ^d   Moretto, G ^a   Fiaschi, A ^b   Smania, N ^b   Giorgetti, P ^c   Antonini, A ^e  

^a Ospedale Civile Borgo Trento   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Ospedale Civile Borgo   (Italy)

^d Centro Parkinson Villa Margherita   (Italy)

^e PARKINSON INSTITUTE   (Italy)

Author keywords

123I FP CIT SPET; Disease progression; Dopamine transporter; Parkinson's disease; UPDRS; Visual assessment

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IOFLUPANE; IOFLUPANE I 123; LEVODOPA; LUGOL; PERGOLIDE; POTASSIUM PERCHLORATE; PRAMIPEXOLE; RADIOLIGAND; ROPINIROLE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG PROTEIN BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MEDICAL SPECIALIST; MOTOR PERFORMANCE; MUSCLE RIGIDITY; NUCLEAR MEDICINE; PARKINSON DISEASE; POST HOC ANALYSIS; QUALITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33846094412     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0718-4     Document Type: Article

References (19)

1. 123I]FP-CIT SPET shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 62:133-140
2. 123I]b-CIT/SPET imaging demonstrates bilateral loss of dopamine transporters in hemiparkinson's disease. Neurology 46:231-237
3. 123I] IBZM-SPET scanning in L-Dopa-naïve Parkinson's disease. Mov Disord 13:438-445.
4. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112:677-692
5. 123I]FP-CIT SPET striatal uptake. Mov Disord 15:692-698
6. Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it? Mov Disord 18[Suppl 7]:43-51
7. 123I]FP-CIT SPET Study Group. Mov Disord 15:503-510
8. 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19:1175-1182
9. Huges AJ, Ben-Sholomo Y, Daniel SE, Lee AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinico-pathological study. Neurology 42:1142-1146
10. Hoehn M, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17:427-442
11. Isaias IU, Benti R, Goldwurm S et al (2006) Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Mov Disord 21:1144-1147
12. Benamer HTS, Oertel WH, Patterson J et al (2003) Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3 month observations. Mov Disord 18:977-984
13. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114:2283-2301
14. 123I]-beta CIT and SPET. Correlation with clinical findings and comparison with multiple system atrophy and progressive nuclear palsy. J Neurol Transm 50:S9-S24
15. Ishikawa T, Dhawan V, Kazumata K et al (1996) Comparative nigrostriatal dopaminergic imaging with iodine 123-βCIT-FP/SPET and fluorine-18-DOPA/ PET. J Nucl Med 37:1760-1765
16. Nurmi E, Ruotinen HM, Kaasinen V et al (2000) Progression in Parkinson disease: A Positron Emission Tomography study with a dopamine transporter ligand [18F] CFT. Ann Neurol 47:804-808
17. Rinne J, Ruottinen H, Bergman J et al (1999) Usefulness of a dopamine transporter PET ligand [18F]b-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 67:737-741
18. Ribeiro MJ, Vidhailet M, Loc'h C et al (2002) Dopaminergic function and dopaminergic transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 59:580-586
19. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38:589-598